Medgenics, Inc. Awarded Grant from the Israeli Office of the Chief Scientist

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) the (“Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that the Company was awarded a government grant amounting to a total net amount of up to NIS 3.0 million ($0.9 million USD), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel for the six month period through August 2011.
MORE ON THIS TOPIC